The AIM-listed biotechnology company said at the 37 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany, that this observational study was conducted in ten sites across Spain. The total 141 patients were evaluated and they demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year.
In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline.
The company, specialising in allergy vaccines, said its modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I.
Allergy Therapeutics said it presented a series of poster presentations at EAACI with key highlights and held a satellite symposium which provided a summary of how adjuvant technologies have evolved.
Manuel Llobet, chief executive officer, said in a statement: “The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength.”
He added: “And we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."